Curaleaf (OTCMKTS:CURLF) Stock Gets Downgrade from Zacks Research

Curaleaf (OTCMKTS:CURLF – Get Free Report) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.

A number of other research analysts also recently commented on CURLF. Citigroup reissued a “buy” rating on shares of Curaleaf in a research report on Thursday, August 6th. UBS Group set a $6.00 target price on shares of Curaleaf in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $6.00.

Get Curaleaf alerts:

Read Our Latest Report on Curaleaf

Curaleaf Price Performance

OTCMKTS:CURLF opened at $8.56 on Tuesday. The stock has a market capitalization of $2.00 billion, a PE ratio of -65.84 and a beta of 1.55. Curaleaf has a 1-year low of $5.40 and a 1-year high of $15.15. The firm has a fifty day simple moving average of $9.91 and a 200 day simple moving average of $8.68. The company has a current ratio of 1.52, a quick ratio of 0.73 and a debt-to-equity ratio of 1.06.

Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.25. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.88%. The firm had revenue of $340.10 million for the quarter, compared to analyst estimates of $332.00 million. On average, research analysts expect that Curaleaf will post 0.01 EPS for the current fiscal year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc is a cannabis company that cultivates, processes, manufactures and sells cannabis products. Through its retail dispensaries and wholesale operations, the company offers flower, pre-rolls, vaporizers, edibles, concentrates, tinctures and other cannabis-derived products for medical and adult-use markets, where permitted by law.

Curaleaf markets products under brands that include Curaleaf, Select and Grassroots. Its business is primarily focused on the United States, where it operates a network of cultivation and processing facilities, dispensaries and distribution operations across multiple state-regulated cannabis markets.

Further Reading

• Five stocks we like better than Curaleaf
• Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test

Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.